Enlivex Therapeutics Ltd. (ENLV) Stock

Enlivex Therapeutics Ltd. is a pioneering clinical-stage company specializing in macrophage reprogramming immunotherapy. At the forefront of its innovative pipeline is Allocetra, a cell-based therapy designed to combat organ dysfunction and failure linked to sepsis. Currently undergoing Phase II clinical trials, Allocetra also shows promise in preclinical trials targeting solid tumors.

Founded in 2005 and headquartered in Nes Ziona, Israel, Enlivex Therapeutics Ltd. has established itself as a leader in developing groundbreaking treatments that harness the power of immunotherapy. The company's commitment to advancing medical science is underscored by its dedication to addressing critical unmet needs in sepsis management and oncology.

Leveraging cutting-edge research and strategic partnerships, Enlivex Therapeutics Ltd. continues to push the boundaries of macrophage reprogramming, aiming to redefine standards of care and improve patient outcomes worldwide.